LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

2006: Revolution in HIV treatment. First EMA approval for single tablet regimen taken once a day

12/08/2021

Nominated by: Gilead Sciences

Organisation in nomination: Gilead Sciences

Antiretroviral therapy (ART) has played an instrumental role in the treatment of HIV, increasing the life expectancy and quality of life of those affected. The first treatments for HIV infection required patients to adhere to complex regimens, consisting of up to 30 tablets per day, some taken every four hours.

In 2006, a new ART was approved by the European Medicines Agency (EMA) as the first treatment that provided a complete treatment regimen in one single tablet, to be taken once daily. This eliminated the possibility of taking partial medication, improved adherence and simplified the treatment regimen.

ART adherence is one of the key determinants of HIV disease progression, with incomplete adherence potentially compromising treatment effectiveness and leading to unsuppressed virus, with the potential for developing HIV drug resistance. By simplifying the treatment regimen, the single tablet ART has supported treatment adherence, helping to advance progress towards the UNAIDS’ goal[1] of viral suppression in 90% of HIV positive people receiving antiretroviral therapy[2].

The breakthrough was celebrated by Dr. Eschenbach, FDA Commissioner, as a “fundamental change to the treatment paradigm” and was approved via the FDA’s fast track scheme, also in 2006[3].

Research in HIV continues and since then treatment approaches have further progressed. However, the breakthrough achieved in 2006 was instrumental in paving the way for modern treatment options benefiting people living with HIV today.

References:

[1] 90-90-90: An ambitious treatment target to help end the AIDS epidemic

[2]  Yiyun Chen, Barriers to HIV Medication Adherence as a Function of Regimen Simplification, 2018

[3] Quote by Dr Andrew von Eschenberg

Back to the list.

Share
Alexandra Simionca
Alexandra Simionca
EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.